Short Report: Pathophysiology Hepcidin levels in diabetes mellitus and polycystic ovary syndrome
Amir H. Sam(Charing Cross Hospital), Kevin G. Murphy(Hammersmith Hospital), Carel W. le Roux(University College Dublin), Stephen R. Bloom(Imperial College London), Dimitris Papamargaritis(University of Leicester), Anjali Amin, Stephen Franks(Imperial College London), Lisa Webber(Singapore General Hospital), Richard Chapman(Imperial College Healthcare NHS Trust), Mark Busbridge(Imperial College Healthcare NHS Trust), Gary Frost(Imperial College London), Norlida Mat Daud(National University of Malaysia), Michelle Sleeth(Hammersmith Hospital), Davinia White(Hammersmith Hospital), Niamh Martin(Hammersmith Hospital), Nurhafzan A. Ismail(Hammersmith Hospital)
Unknown
January 1, 2013
Cited by 0
Related Papers
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism
|Nature Communications|2014|1.7k
Inhibition of Food Intake in Obese Subjects by Peptide YY<sub>3–36</sub>
|New England Journal of Medicine|2003|1.6k
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.5k
Human distribution and release of a putative new gut hormone, peptide YY
|Gastroenterology|1985|1.1k